H5 antigen
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 7, 2022 (NCT05397119)
Timeline
Indications
Studied for
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06560151 | Phase 2 | Aug 21, 2024 | Department of Health and Human Services, ICON, Rho, Inc. |
| NCT05397119 | Phase 1 | Jul 7, 2022 | BlueWillow Biologics, National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BlueWillow Biologics | For profit | 1 | 1 | 1 | 2022 |
| Department of Health and Human Services | Government | 1 | 1 | 1 | 2024 |
| ICON | For profit | 1 | 0 | 1 | 2024 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2022 |
| Rho, Inc. | For profit | 1 | 0 | 1 | 2024 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1